Buy & Sell American States Water Company (AWR) – American States Water Company Price Today
Key Stats
- $2.97BMarket Cap
- UtilitiesSector
- -6.92%3M Drawdown
- $3.88BEnterprise Value
- 2.66%Dividend Yield
- 16 daysTypical Hold Time
American States Water Company (AWR) is currently valued at a market capitalization of $2.97B, with an enterprise value of $3.88B. Over the past 52 weeks, American States Water Company has traded between a low of $70.1 and a high of $80.8, highlighting its annual price range. Over the past three months, American States Water Company has recorded a drawdown of -6.92%, reflecting recent price volatility. American States Water Company offers a dividend yield of 2.66%, with the most recent dividend of $0.50 paid on 18 May 26. On average, investors hold American States Water Company for approximately 16 days, indicating typical investor behavior on the platform.
About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Most Recent News
Boston Scientific invests $1.5B for stake in MiRus, targeting advanced aortic stenosis treatment.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Elliott sees hidden value in Bio-Rad via $5B Sartorius stake amid share price slump
Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories, which develops medical instruments and software. Bio-Rad's founding family retains majority voting control, complicating activist efforts. Elliott ...
Regeneron's melanoma trial fails, stock drops over 10%, investors urged to explore legal options.
Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's ...
